AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients.
作者： Jordi Remon , David Planchard
DOI: 10.2217/FON.15.250
关键词:
摘要: Non-small-cell lung cancer (NSCLC) patients whose tumors have an EGFR-activating mutation develop acquired resistance after a median of 9–11 months from the beginning treatment with erlotinib, gefitinib and afatinib. T790M is cause this in approximately 60% cases. AZD9291 oral, irreversible, mutant-selective EGF receptor (EGFR) tyrosine kinase inhibitor (TKI) developed to potency against EGFR mutations, including mutation, while sparing wild-type EGFR. A Phase I trial EGFR-mutant NSCLC patients, demonstrated high activity, essentially among T790M-mutant tumors, manageable tolerability profile. Ongoing III trials are evaluating as first-line compared erlotinib gefitinib; second-line chemotherapy progression on TKI tumors. Better identification post relapse mechanisms AZD9...
futuremedicine.com
sci-hub.se 参考文章(62)
Kenneth S Thress, Cloud P Paweletz, Enriqueta Felip, Byoung Chul Cho, Daniel Stetson, Brian Dougherty, Zhongwu Lai, Aleksandra Markovets, Ana Vivancos, Yanan Kuang, Dalia Ercan, Sarah E Matthews, Mireille Cantarini, J Carl Barrett, Pasi A Jänne, Geoffrey R Oxnard, Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M Nature Medicine. ,vol. 21, pp. 560- 562 ,(2015) , 10.1038/NM.3854
Akito Hata, Nobuyuki Katakami, Hiroshige Yoshioka, Jumpei Takeshita, Kosuke Tanaka, Shigeki Nanjo, Shiro Fujita, Reiko Kaji, Yukihiro Imai, Kazuya Monden, Takeshi Matsumoto, Kazuma Nagata, Kyoko Otsuka, Ryo Tachikawa, Keisuke Tomii, Kei Kunimasa, Masahiro Iwasaku, Akihiro Nishiyama, Tadashi Ishida, Yoshihiro Nishimura, Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations. Cancer. ,vol. 119, pp. 4325- 4332 ,(2013) , 10.1002/CNCR.28364
Robert C. Doebele, Xian Lu, Christopher Sumey, DeLee A. Maxson, Andrew J. Weickhardt, Ana B. Oton, Paul A. Bunn, Anna E. Barón, Wilbur A. Franklin, Dara L. Aisner, Marileila Varella-Garcia, D. Ross Camidge, Oncogene status predicts patterns of metastatic spread in treatment‐naive nonsmall cell lung cancer Cancer. ,vol. 118, pp. 4502- 4511 ,(2012) , 10.1002/CNCR.27409
Akihiro Nishiyama, Kazuya Monden, Kosuke Tanaka, Masahiro Iwasaku, Nobuyuki Katakami, Kei Kunimasa, Keisuke Tomii, Akito Hata, Katsuhiro Masago, Ryo Tachikawa, Yoshihiro Nishimura, Shiro Fujita, Takeshi Matsumoto, Jumpei Takeshita, Yukihiro Imai, Reiko Kaji, Hiroshige Yoshioka, Kazuma Nagata, Tadashi Ishida, Kyoko Otsuka, Prognostic Impact of Central Nervous System Metastases After Acquired Resistance to EGFR-TKI: Poorer Prognosis Associated with T790M-negative Status and Leptomeningeal Metastases Anticancer Research. ,vol. 35, pp. 1025- 1031 ,(2015)
D. Planchard, Y. Loriot, F. André, A. Gobert, N. Auger, L. Lacroix, J.C. Soria, EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients Annals of Oncology. ,vol. 26, pp. 2073- 2078 ,(2015) , 10.1093/ANNONC/MDV319
Matthew J. Niederst, Haichuan Hu, Hillary E. Mulvey, Elizabeth L. Lockerman, Angel R. Garcia, Zofia Piotrowska, Lecia V. Sequist, Jeffrey A. Engelman, The allelic context of the C797S mutation acquired upon treatment with third generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies Clinical Cancer Research. ,vol. 21, pp. 3924- 3933 ,(2015) , 10.1158/1078-0432.CCR-15-0560
L.E.L. Hendriks, E.F. Smit, B.A.H. Vosse, W.W. Mellema, D.A.M. Heideman, G.P. Bootsma, M. Westenend, C. Pitz, G.J. de Vries, R. Houben, K. Grünberg, M. Bendek, E.-J.M. Speel, A.-M.C. Dingemans, EGFR mutated non-small cell lung cancer patients: More prone to development of bone and brain metastases? Lung Cancer. ,vol. 84, pp. 86- 91 ,(2014) , 10.1016/J.LUNGCAN.2014.01.006
L. V. Sequist, B. A. Waltman, D. Dias-Santagata, S. Digumarthy, A. B. Turke, P. Fidias, K. Bergethon, A. T. Shaw, S. Gettinger, A. K. Cosper, S. Akhavanfard, R. S. Heist, J. Temel, J. G. Christensen, J. C. Wain, T. J. Lynch, K. Vernovsky, E. J. Mark, M. Lanuti, A. J. Iafrate, M. Mino-Kenudson, J. A. Engelman, Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors Science Translational Medicine. ,vol. 3, ,(2011) , 10.1126/SCITRANSLMED.3002003
Suresh S Ramalingam, Pasi A Jänne, Tony Mok, Kenneth O'Byrne, Michael J Boyer, Joachim Von Pawel, Adam Pluzanski, Mikhail Shtivelband, Lara Iglesias Docampo, Jaafar Bennouna, Hui Zhang, Jane Q Liang, Jim P Doherty, Ian Taylor, Cecile B Mather, Zelanna Goldberg, Joseph O'Connell, Luis Paz-Ares, Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): A randomised, double-blind, phase 3 trial Lancet Oncology. ,vol. 15, pp. 1369- 1378 ,(2014) , 10.1016/S1470-2045(14)70452-8
Young Joo Lee, Hye Jin Choi, Se Kyu Kim, Joon Chang, Jin Wook Moon, In Kyu Park, Joo-Hang Kim, Byoung Chul Cho, Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer Cancer. ,vol. 116, pp. 1336- 1343 ,(2010) , 10.1002/CNCR.24877